1. Home
  2. REED vs XCUR Comparison

REED vs XCUR Comparison

Compare REED & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reed's Inc.

REED

Reed's Inc.

HOLD

Current Price

$0.74

Market Cap

9.1M

Sector

N/A

ML Signal

HOLD

Logo Exicure Inc.

XCUR

Exicure Inc.

HOLD

Current Price

$1.37

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
XCUR
Founded
1987
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
9.2M
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
REED
XCUR
Price
$0.74
$1.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
96.1K
38.9K
Earning Date
05-12-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
83.37
EPS
N/A
N/A
Revenue
$34,065,000.00
N/A
Revenue This Year
$18.74
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.05
52 Week High
$5.97
$9.48

Technical Indicators

Market Signals
Indicator
REED
XCUR
Relative Strength Index (RSI) N/A 46.89
Support Level N/A $1.20
Resistance Level N/A $1.48
Average True Range (ATR) 0.00 0.11
MACD 0.00 0.03
Stochastic Oscillator 0.00 46.81

Price Performance

Historical Comparison
REED
XCUR

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: